Plecanatide is a uroguanylin analogue and guanylate-cyclase-C agonist with approved constipation indications. It is designed to act locally in the gastrointestinal tract and is minimally absorbed systemically at labelled oral doses.

Established. Review the research and limitations before relying on this record.

Plecanatide and its active metabolite activate intestinal GC-C, increasing cyclic GMP and promoting fluid secretion and transit. The relevant biology is local gastrointestinal signalling rather than sustained systemic peptide exposure.

The cited label reports that plecanatide and its active metabolite are generally not measurable in plasma after the recommended dose. Both are processed in the gastrointestinal tract by loss of the terminal leucine and proteolytic degradation, so standard plasma pharmacokinetic parameters cannot be calculated.

U.S. labelling supports treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in specified adults. This evidence should not be transferred to systemic, injectable or unregulated products marketed under a peptide framing.

Diarrhoea is the key labelled adverse reaction. Plecanatide is contraindicated in patients younger than six years because of dehydration risk and in people with known or suspected mechanical gastrointestinal obstruction.

This is a source-backed medicine and safety summary, not a recommendation or a protocol. Product labels, approvals, contraindications, interactions and availability differ by jurisdiction; check the current official product information and consult a qualified clinician.